Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05344482 · ClinicalTrials.gov registry record
Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 277
- Enrollment target
NCT05344482 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 277 participants.
The verdict
NCT05344482 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 277 participants
- Enrollment target
Study Summary
This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.
Interventions
- OTHER Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2021-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05344482
The ClinicalTrials.gov registry entry for NCT05344482 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05344482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05344482 about?
NCT05344482 is a clinical study titled "Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis". This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.
What is the current status of trial NCT05344482?
This trial is currently completed. The enrollment target is 277 participants. The study started on 2020-07-09. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT05344482?
The interventions under investigation include: Secukinumab (OTHER).
Who is sponsoring clinical trial NCT05344482?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.